messag expect beat trikafta vs con
follow revenue guidanc also came well ahead consensu
vs like still conserv view commentari pipelin
consist recent messag remain encourag progress earlier
stage program see recent deep dive deck expect data updat
year help unlock addit valu particular continu think
approach initi thought kol takeaway interest
look forward move clinic later year/earli next reiter buy
rais pt
compani data factset data guggenheim secur llc note million except per share data
compani data factset
rais pt vs prev base model updat reflect
result revenu assumpt adjust trikafta launch dynam reiter
buy rate
page analyst certif import disclosur
compani report guggenheim secur llc research
page analyst certif import disclosur
base dcf valuat arriv pt forecast probability-weight revenu expens assum
discount rate termin growth rate po gene therapi po aatd fsg program
po program base result adjust revenu assumpt trikafta launch dynam
rais pt previous
suscept risk appli entir biotech industri includ develop regulatori commerci
manufactur financ ip risk specif includ
clinic risk delay clinic trial initi unexpect safeti issu efficaci lower expect
regulatori risk clinic trial ultim success possibl vrtx medicin approv global regulatori
agenc given novelti technolog agenc may requir addit long-term data could delay potenti
ip risk crispr landscap rapidli evolv guarante access new develop
technolog emerg space
competitor risk technolog wide follow public media possibl news
technolog unrel /crsp could lead downsid share
page analyst certif import disclosur
mm except per share data
factset consensu
total incom expens net
incom tax
loss attribut non-controlling interest
net incom attribut
non-gaap net incom attribut
factset consensu
gaap cog tot prod sale
 tot revenu
sg tot revenu
compani report guggenheim secur llc estim
page analyst certif import disclosur
